Clavulanic acid - Rexahn

Drug Profile

Clavulanic acid - Rexahn

Alternative Names: Clavulanic acid CR - Rexahn; Clavulanic acid extended-release (Serdaxin) - Rexahn; Clavulanic acid IR - Rexahn; RX-10100; Serdaxin; Zoraxel

Latest Information Update: 28 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revaax Pharmaceuticals
  • Developer National Institute of Neurological Disorders and Stroke; Rexahn Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antidepressants; Anxiolytics; Azetidines; Carboxylic acids; Erectile dysfunction therapies; Neuroprotectants; Oxazolidinones; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Dopamine release stimulants; Serotonin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction; Major depressive disorder

Highest Development Phases

  • Discontinued Anxiety disorders; Erectile dysfunction; Major depressive disorder; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 27 Jun 2014 Clavulanic acid - Rexahn is available for licensing as of 21 Mar 2014.
  • 21 Mar 2014 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
  • 21 Mar 2014 Discontinued - Phase-II for Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top